December 18, 2017 / 1:12 PM / 9 months ago

BRIEF-Allergan And Richter Announce Positive Topline Results From Phase 3 Study Of Cariprazine For Treatment Of Bipolar I Depression

Dec 18 (Reuters) - Allergan Plc:

* ALLERGAN AND RICHTER ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY OF CARIPRAZINE FOR THE TREATMENT OF BIPOLAR I DEPRESSION

* ALLERGAN PLC - IN THE STUDY, PRIMARY EFFICACY OBJECTIVE WAS MET FOR BOTH CARIPRAZINE 1.5MG AND 3MG DOSE GROUPS

* ALLERGAN PLC - PLANS TO SUBMIT A SUPPLEMENTAL NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION IN 2ND HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below